Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Moorslede – page 151

2 287 clinical trials in Moorslede, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Moorslede at a glance
2 287
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 287 trials in Moorslede

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Teclistamab and Drug Combination for Newly Diagnosed Multiple Myeloma Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Acute myeloid leukaemia+2

Not recruiting

Study on the Safety and Effectiveness of Quizartinib for Children and Young Adults with Acute Myeloid Leukemia (AML)

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Daiichi Sankyo Inc.

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Hypertension

Not recruiting

Study on Baxdrostat for Lowering Blood Pressure in Patients with Resistant Hypertension

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Utreloxastat
  • Sponsor:PTC Therapeutics Inc.

Cholangiocarcinoma

Not recruiting

Study of Tucatinib and Trastuzumab for Patients with Advanced Solid Tumors with HER2 Changes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Seagen Inc.

Colitis ulcerative+2

Not recruiting

Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn's Disease, or Unclassified Inflammatory Bowel Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Belgian IBD Research and Development

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Moorslede

What the registry says about research in the country

01 Gastroenterology Research

Innovative clinical trials focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research evaluates different approaches to medication management for individuals with functional dyspepsia and reflux conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

The research explores on-demand medication use and alternative therapeutic options, aiming to establish optimal treatment withdrawal protocols while maintaining patient comfort and health outcomes.

02 Digestive Health Studies

Clinical investigations centered on managing heartburn and related digestive conditions through innovative treatment approaches. The research examines the effectiveness of alginate-based alternatives and intermittent dosing strategies.

  • Medication Optimization
  • Alternative Therapies
  • Patient-Centered Approaches

This primary care research initiative aims to enhance treatment protocols for patients requiring long-term digestive health management.

03 Primary Care Innovation

Forward-thinking research in primary care settings exploring evidence-based approaches to medication management. The study compares traditional and innovative methods for reducing long-term medication dependency.

  • Clinical Practice Improvement
  • Patient Safety Protocols
  • Treatment Optimization

The research focuses on developing practical, patient-friendly approaches to medication reduction while maintaining therapeutic effectiveness.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.